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ELEVATION OF CARDIAC GLYCOLYSIS REDUCES PYRUVATE 
DEHYDROGENASE BUT INCREASES GLUCOSE OXIDATION 
Qianwen Wang 
April 1, 2011 
Heart failure is the most frequent cause of mortality in western countries. Currently, 
there is no cure treatment for heart failure and the long term survival rate following heart 
failure is poor, with one third of patients dying within a year of diagnosis. Thus, new 
therapeutic targets have to be developed. 
Enhanced glycolysis is a very common phenomenon in the development of heart 
failure and maybe a target for drug development. However it is not know whether the 
increased glycolysis is a cause or an effect of heart failure. Also, metabolic modulators to 
increase glucose use by the heart have been used acutely in treatment in heart failure but 
the long term impact of increased glycolysis is not known. To understand whether 
chronically increased glycolysis specifically in the heart is beneficial or detrimental, 
glycolysis was chronically elevated by cardiac-specific overexpression of a modified, 
phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2) in 
transgenic mice. PFK-2 controls the level offructose-2, 6-bisphosphate (Fru-2, 6-P2), an 
important regulator of phosphofructokinase and glycolysis. These transgenic mice were 
used to test two hypotheses: (1) Long term elevation of cardiac Fru-2, 6-P2 will increase 
IV 
glycolysis and alter glucose oxidation. (2) Chronically increased cardiac glycolysis will 
be detrimental to the heart. 
To test these hypotheses we carried out three specific aims: Aim I was to produce 
transgenic mice with overexpression of phosphatase-deficient 6-phosphofructo-2-
kinase/fructose-2, 6-bisphosphatase (PFK-2). Aim 2 was to compare metabolites and 
glucose metabolism in transgenic and control samples using whole hearts, Langendorff 
perfused hearts and cultured adult cardiomyocytes. Aim 3 was to assess whether 
chronically increased glycolysis promotes cardiac fibrosis, hypertrophy or impaired 
function. 
The results demonstrated a new line of transgenic mice called Mk, with cardiac 
expression of modified PFK2 and increased levels ofFru-2, 6-P2. Mk hearts had elevated 
glycolysis that was less sensitive to inhibition by palmitate. Mk cardiomyocytes had 
increased glucose oxidation despite reduced pyruvate dehydrogenase complex (PDC) 
activity. PDC activity was decreased because of reduced protein levels of PDC subunit 
Ela and because of increased PDC Ela phosphorylation. Mk hearts had increased 
mitochondrial level of MCT -2 transporter protein and malate content. The increased 
malate content and elevated MCT2 expression suggested that anaplerosis pathways in 
transgenic hearts might explain the paradoxical finding of reduced PDC activity and 
elevated glucose oxidation. 
Functional studies revealed that the elevation in glycolysis made transgenic 
cardiomyocytes highly resistant to contractile inhibition by hypoxia, in vitro. However, in 
vivo the trans gene had no protective effects on ischemia-reperfusion injury. Furthermore, 
the transgenic hearts exhibited pathologic changes that included a 17% increase of the 
v 
heart weight-to-body weight ratio, greater cardiomyocyte length and increased cardiac 
fibrosis. Therefore, chronic elevation of glycolysis produced more pathological effects 
than protective effects on the heart. 
VI 
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INTRODUCTION 
Significance and Background 
Heart failure, the most frequent cause of mortality in the western countries, is more 
prevalent than all cancers combined (71). Currently, no cure treatment for heart failure is 
available, and the long term survival rate following heart failure is poor, with one third of 
patients dying within a year of diagnosis (10). Thus, studies, focusing on identifying new 
therapeutic targets to prevent or reverse cardiac hypertrophy from the transition to heart 
failure, have to be developed. 
In the development of heart failure, cardiac hypertrophy serves as an important risk 
factor and is explained largely by an increase in cardiac myocyte size due to pathological 
overload. In addition to structural changes in the myocardium, an altered utilization of 
cardiac metabolic substrate glucose is recognized as one of the biochemical hallmarks of 
the hypertrophied and failing heart (42). In the fetal heart, glucose is the primary cardiac 
substrate while fatty acid metabolism is reduced due to carnitine deficiency and delayed 
maturation of enzymes involved in fatty acid oxidation. In the healthy heart under resting 
conditions, the oxidation of fatty acid covers about 70% of the cardiac energy demand, 
with additional significant contributions from glucose and lactate (Figure 1). During the 
normal physiological growth of the heart including pregnancy-induced growth and 
exercise-induce cardiac hypertrophy, glucose utilization (includes glycolysis and glucose 
1 
oxidation) and fatty acid oxidation are enhanced. However, in the development of 
pathological cardiac hypertrophy and heart failure, fatty acid oxidation decreases, 
glycolysis increases while glucose oxidation varies (increases, decreases or no change) 
(10). Elevated glycolysis is considered to be an adaptive response to compensate for the 
reduced energy efficiency of the compromised heart (53). On the other hand, rather than 
being an adaptive response, elevation of cardiac glucose metabolism may be an example 
of the prominent reversion to fetal gene expression that occurs during heart failure (76). 
Decoupling of the rate of glucose oxidation from the rate of glycolysis has been 
demonstrated in experimental models of heart failure, and this is potentially detrimental 
to long term cardiac function (49). However it is not certain whether decoupling is a 
direct consequence of elevated glycolyisis, or it occurs only in the context of heart 
failure. 
2 
Diabetes Reduces Glycolysis 
Diabetes is one of the major risk factors in the development of heart failure, and 
diabetes has major effects on cardiac fuel metabolism. In the normal heart the rate of 
glycolysis is responsive to changing metabolic demand (8). In diabetes there is a marked 
reduction in the ability of the cardiac myocyte (75) to accelerate glycolytic rate due to 
decreased glycolytic capacity. This reduction in cardiac glucose usage is found both in 
the hearts of diabetic patients (4, 14, 80) and in experimental models of diabetes (75). 
Metabolic flux analysis (37) demonstrates that control of cardiac glycolysis is not limited 
to a single metabolic step; rather it is shared by several reactions, depending on ambient 
conditions. In the diabetic myocyte there is decreased activity in several critical steps of 
the glycolytic pathway ensuring that overall rate of glycolysis is impaired. Activity of 
glucose transporters (75), hexokinase (17), 6-phosphofructo-1-kinase (PFK) (55) and 
glyceraldehyde-3-phosphate dehydrogenase (19) all decline in diabetes. Mechanisms for 
reduced enzyme activity are multiple but include reduced gene expression for glucose 
transporters and hexokinase (12, 22) and elevated concentrations of metabolic inhibitors 
for hexokinase (15) glyceraldehyde-3-phosphate dehydrogenase and PFK (16). 
In addition to reduced glucose usage, diabetic hearts also display an abnormally large 
reliance on fatty acid oxidation for energy. It has been proposed that this contributes to 
the development of diabetic cardiomyopathy (68). Fatty acids are the major source of 
fuel in the normal heart. But in diabetes this reliance is exaggerated. In part this is due to 
elevated circulating lipids. But it also appears to be a function of decreased glucose 
metabolism. Glucose metabolism produces increased intracellular levels of malonyl CoA 
3 
(5), a potent inhibitor of fatty acid conjugation to camitine. This step is a major control 
point for movement of fatty acids into the mitochondria for oxidation. With reduced 
glucose metabolism, one of the normal braking systems for oxidation of lipids is lost. 
Reduced Glycolysis and Diabetes Increase Vulnerability to Ischemic Damage 
The reduced glycolytic activity of the diabetic heart is an important factor that 
predisposes to ischemic or hypoxic damage. In ischemic (54) hearts, dependence on 
glucose and glycolysis increases markedly. One of the protective responses of the heart is 
an increase in glycolysis (69, 74). In fact, stimulation of glycolysis with glucose and 
insulin has been used for many decades to protect patient hearts from ischemic or 
hypoxic damage (60,61). In vitro experiments analyzing glycolysis and ischemia support 
this clinical practice. Studies in isolated perfused hearts reveal that manipulations to 
accelerate cardiac glucose use decrease ischemic damage (62, 83) while procedures that 
limit glycolysis tend to sensitize the heart to ischemia (31). In one of the genetic 
modification studies in this area, Tian et aI., (78) found that cardiac specific knockout of 
the GLUT4 glucose transporter, a mutation that reduces cardiac glycolysis, sensitizes the 
heart to hypoxic damage. They proposed that the damage was similar to the damage seen 
in diabetic hearts. It is also established that one protective response of the heart to 
ischemic stress is a significant increase in glycolysis. 
Diabetes reduces glycolysis, and studies of diabetic models reveal exacerbated 
ischemic damage that confirm the outcome found in diabetic patients. However, certain 
experimental variables can alter this outcome. The enhanced sensitivity of the heart is 
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most apparent when the diabetes is of long duration (66). Also, the diabetic deficit may 
be hidden if it is tested following complete blockage of flow. This is thought to be a 
function of lactate buildup in normal hearts (20, 38) which occurs during complete 
obstruction of flow. Diabetic hearts are protected from lactate build up by their lower 
rates of glycolysis (20, 38). Studies that use chronic models of diabetes and reduced 
flow, rather than zero flow ischemia find that diabetes increases ischemic damage (66). 
The mechanism of glucose induced cardiac protection in ischemia has not been 
resolved. However, it is clear that glycolysis becomes the sole or primary source of ATP 
production in hypoxic hearts. Also, ATP derived from glycolysis seems to have a 
preferential role (85) in maintaining normal conductances for calcium, potassium and 
sodium ions, functions that are critical in maintaining cardiac myocytes viability during 
ischemia. Glycolytic enzymes are located in close proximity to the ATP dependent 
sarcoplasmic reticulum calium pump (90) and the ATP regulated potassium channel(86). 
Active glycolysis has been shown to be critical in the activity of the sarcoplasmic calcium 
pump (90) and the ATP-sensitive potassium channel (86). 
Reduced Glycolysis Predisposes to Cardiomyopathy 
Genetic mutations, whether natural (3) or experimental (77), that impair glycolysis 
produce cardiac pathology. The most prominent finding in glucose transporter (GLUT4) 
knockout mice is cardiac hypertrophy (77). When additional knockout mice were made 
in which cre-IoxP technology was used to confine the GLUT4 knockout to the heart, 
cardiac hypertrophy was still observed (1). These results indicate that chronic impaired 
5 
glucose metabolism promotes cardiac damage. Conversely it appears that enhanced 
glycolysis may prevent diabetic cardiomyopathy. A report by Belke et at, described the 
effect of overexpression of the GLUT4 glucose transporter on diabetic cardiomyopathy in 
(7). They found that db/db mice with a glucose transporter transgene had markedly 
improved cardiac contractility compared to nontransgenic db/db mice. However, 
conclusions based on this exciting result must be tempered by the fact that the glucose 
transporter trans gene was active in many tissues. Cardiac protection may have been 
secondary to extra-cardiac actions of the trans gene, such as reductions in blood glucose 
levels (23). 
A number of findings from non-genetic studies support the hypothesis that altered 
glucose metabolism can contribute to cardiomyopathy. Apoptosis of cardiac myocytes, 
which is known to occur during heart failure (52), is inhibited by manipulations that 
increase glycolysis (50). Bishop and Altrud (ll)reported 30 years ago that glycolytic 
metabolism is increased in cardiac hypertrophy and congestive heart failure. This may be 
an adaptive mechanism to take advantage of the higher yield of ATP from carbohydrate 
metabolism. Studies utilizing in vitro application of inhibitors of glucose metabolism, 
such as 2-deoxyglucose report weakened contractility, even under well-oxygenated 
conditions (36). Notably, the most prominent finding described was impaired diastolic 
relaxation, which is also the most prominent defect in diabetic cardiomyopathy (73). 
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Therapeutic Implications 
Traditional clinic treatment of heart failure involves management of risk factors and 
control of symptoms by using angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, beta blockers, diuretics, aldosterone antagonists and digitalis. 
However, these classic agents for treating heart failure have direct hemodynamic, 
inotropic or chronotropic effects, with significant potential for morbidity and mortality. 
Recently, metabolic modulators, such as trimetazidine, ranolizine, perhexiline and 
estomoxir, and other drugs have been developed as a new class of drugs that may act by 
shifting substrate utilization from fatty acid to glucose utilization, either directly through 
stimulation of glycolysis or indirectly through inhibition of fatty acid oxidation 
(63).Under normal physiological conditions, oxidation of fatty acid can yield higher ATP 
amounts compared with the oxidation of glucose (129 A TP per palmitate molecule versus 
36 ATP per glucose molecule). However, in terms of oxygen cost, the oxidation of 
glucose is more efficient (ATP/O~3.1) than that of fatty acid (ATP/O~2.8). This means 
that switching from fatty acid utilization toward glucose oxidation is approximately 11 % 
more economical in terms of oxygen cost in the heart (81). Therefore, the fact that 
metabolic modulators can shift the heart to use more glucose is thought to be beneficial. 
However, all these metabolic modulators are only acutely used in treatment in heart 
failure and the impact of increased glycolysis by this class of drugs on overall mortality 
for the long term use is still under investigation. (63) In order to reveal long term effects 
of increased cardiac glucose utilization on heart, a transgenic mice model (Mk) with 
7 
chronically cardiac specific increased glycolysis by overexpression of kinase active PFK-
2 was established. 
PFK-l trans gene and Transgenic mice 
The control of cardiac glycolysis is shared by several reactions (37). One of the 
control reactions is carried out by 6-phosphofructo-l-kinase (PFK-l) (29, 55), which 
catalyzes the phosphorylation of fructose-6-phosphate (F6P) to fructose-l ,6-bisphosphate 
(Fru-l,6-P2). F6P is in equilibrium with glucose-6-phosphate (G6P), and these two sugars 
initiate glycogen synthesis, the hexosamine pathway, and the hexose monophosphate 
shunt. Thus, PFK-l not only has an important role in regulating glycolysis but, by 
controlling the metabolism ofF6P, PFK-l can also modulate several important reactions 
branching off of glycolysis. PFK -I activity is tightly controlled and negatively regulated 
by products of fat metabolism, including A TP and citrate. The most important positive 
regulator ofPFK-1 is fructose-2, 6-bisphosphate (Fru-2, 6-P2). The bifunctional enzyme 
6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2) catalyses the synthesis 
and degradation of Fm-2, 6-P2. PFK-2 is, in tum, regulated by a complex network of 
kinases, phosphatases, and metabolites (59). In this study, we used a cardiac-specific 
trans gene for a mutant form of liver PFK-2 to directly elevate cardiac Fru-2, 6-P2 and 
increase glycolysis without inducing heart failure. 
8 
Hypothesis and Aims 
To understand whether chronically increased glycolysis specifically in the heart is 
beneficial or detrimental, glycolysis was permanently elevated by cardiac-specific 
overexpression of a modified, phosphatase-deficient 6-phosphofructo-2-kinase/fructose-
2, 6-bisphosphatase (PFK-2) in transgenic mice. PFK-2 controls the level offructose-2, 
6-bisphosphate (Fru-2, 6-P2), an important regulator of phosphofructokinase and 
glycolysis. These transgenic mice were used to test two hypotheses: (1) Long term 
elevation of cardiac Fru-2, 6-P2 will increase glycolysis and alter glucose oxidation. (2) 
Chronically increased cardiac glycolysis will be detrimental to the heart. 
To test these hypotheses the following specific aims were carried out: 
Specific Aim 1: Produce transgenic mice with overexpression of phosphatase-deficient 6-
phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2). 
Specific Aim 2: Compare metabolites and glucose metabolism in transgenic and control 
samples using whole hearts, Langendorff perfused hearts and cultured adult 
cardiomyocytes. 
Specific Aim 3: Assess whether chronically increased glycolysis promotes cardiac 
fibrosis, hypertrophy or function. 
9 
METHODS AND MATERIALS 
Animals 
The bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
(PFK2) controls levels ofF-2,6-P2 by catalyzing two opposing reactions: Fru6P + ATP 
-)- Fru-2,6-P2 + ADP and Fru-2,6-P2 -)- F6P + Pi. The development of the kinase 
activeibisphosphatase deficient PFK2 mutant has been previously described (38,86). 
Cardiac specific expression was obtained by ligating a 1.6 kb KpnIlHindIII fragment of 
kinase active liver PFK2 (86) behind the a-myosin heavy chain (MHC) promoter(22). 
The transgene was designated Mk (for the MHC promoter and the kinase active PFK2 
gene). Transgenic mice were produced on a FVB background and maintained as 
heterozygotes by breeding to FVB mice. Standard embryo microinjection procedures 
were used for producing transgenic animals. All procedures conformed to the Guide for 
the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996) and were approved by the USDA 
certified. 
PFK-2 Expression Analysis 
PFK-2 protein was analyzed by western blot analysis as previously reported (17). In 
brief, PFK-2 was extracted from fresh hearts by homogenization in buffer containing 20 
10 
mM N-[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid (TES), 1 mM 
dithiothreitol, 100 mM KCl, 5 mM Ethylenediaminetetraacetic acid (EDTA), 5 mM 
Ethylene glycol-bis(~-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) (pH 7.8), 1.2 
mM phenylmethylsulfonyl fluoride, 2.5 mg/liter leupeptin. After precipitation with 40% 
PEG, the pellet was dissolved in buffer containing 20 mM TES, 1 mM dithiothreitol, 100 
mM KCl, 0.1 mM EDTA (pH 7.5), 0.5 mM phenylmethylsulfonyl fluoride, 2.5 mg/liter 
leupeptin. The concentration of extracted protein was measured by the BCA method 
(Pierce Chemical Co.). Equal amounts of extracted protein (100 Ilg) were used for 
Western blots. Rabbit anti-rat liver PFK-2 serum was used as primary antibody at a 
1: 1 ,000 dilution. Bands were visualized using horseradish peroxidase-conjugated goat 
anti-rabbit secondary antibody and enhanced luminol-based chemiluminescent (ECL). 
(Amersham Life Science, Buckinghamshire, UK) 
Measurement of Metabolites 
For the assay ofG6P, F6P and Fru-l,6-P2, hearts were homogenized in 1 Mice-cold 
perchloric acid and centrifuged. The supernatants were neutralized with 2 M KHC03. 
The supernatant from neutralized tissue extracts was used for estimation of these 
metabolites by fluorometric method (45) . 
Cardiac F-2,6-P2 was extracted from fresh heart tissue in 10-20 volumes of 50 mM 
NaOH and kept at 80°C for 5 minutes. The extract was cooled and neutralized at O°C by 
the addition of ice-cold 1 M acetic acid in the presence of 20 mM HEPES. After 
centrifugation at 8,000g for 10 minutes, supernatant was collected and assayed for Fru-
2,6-P2 by the PFK-l activation method(80). For the assay of Fru-2, 6-P2, the buffer 
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containing pHS.O 100mM TES, 6mM MgCh, 1mM EDTA, O.lmM Dithiothreitol (OTT), 
0.22mM ~-Nicotinamide adenine dinucleotide (NADH), 100mM F-6-P, 10mg/mi 
PPi:PFK-1, aldolase, Glycero-3-phosphate Dehydrogenase (GDH), Triosephosphate 
isomerase (TIM). The reaction mixtures were kept at 30°C for 10 min, then read by 
spectrophotometer at 340nm wave length. 
F or the assay of glycogen snap frozen tissue was weighed, homogenized in 9 vol. of 
30% KOH at O°C and then heated at 70°C for 30 min. The glycogen was precipitated 
with absolute alcohol and saturated sodium sulfate and re-dissolved in 0.1 M acetate 
buffer, pH 4.7. Then 10 III of homogenate glycogen was hydrolyzed to glucose by the 
addition of 50 ng amyloglucosidase (Boehringer-Mannheim) in 100 III of O.l M acetate 
buffer. Glucose was then measured by fluorometric assay using hexokinase and glucose-
6-phosphate dehydrogenase as we reported earlier (42). 
Cardiac Perfusion 
Langendorffperfusions were carried out as we previously described (41,42). The 
heart was rapidly canulated through the aorta and retrogradely perfused at 2 mllmin with 
Krebs-Henseleit buffer (KH) consisting of 120 mM NaCl, 20 mM NaHC03, 4.6 mM 
KCI, 1.2 mM KH2P04, 1.2 mM MgCh, 1.25 mM CaCh, 5 mM glucose. Throughout the 
perfusion KH buffer was continuously equilibrated with 95% 0 2/5% CO2 which 
maintained a pH of 7.4 and temperature was maintained at 37°C. The heart was paced 
throughout the procedure at 6 Hz (6 V, 3 ms). Perfusion pressure and contractility was 
monitored continuously during the perfusion, as described previously (41, 42). 
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Measurements of glycolysis, palmitate oxidation and lactate production in perfused 
hearts 
Glycolysis was measured using [5-3H]glucose as the substrate as we have previously 
reported (7). For studying the effect of insulin, baseline glycolysis was determined for the 
first 30 min followed by 50 min in the presence of 200 f.lU/ml insulin. Glycolysis in the 
presence of palmitate was measured by bringing the perfusate to O.4mM palmitate (7) by 
addition of 1/20th volume of 8mM palmitate bound to 10% Albumin from bovine serum 
(BSA) in KH buffer. 
Lactate production and glycolysis measurement with 5}H-glucose were performed 
with perfusion buffer containing 5 mM glucose as previously described (17). Palmitate 
oxidation was measured by perfusion with 5 mM glucose plus 0.4 mM palmitate 
containing 0.75 /lei per ml [9, lO}H] palmitate. Tritiated water produced from tritiated 
glucose or palmitate during cardiac perfusion was measured by diffusion and scintillation 
counting. Effluent from each time point of the perfusion was assayed in duplicate. For 
each experiment, background counts were determined by performing the same 
equilibration on perfusion buffer that had not passed through the heart. Diffusion 
efficiency was measured in each experiment using tritiated water. Lactate concentration 
was measured in 6-fold diluted effluent using Eaton Bioscience Inc. Kit-11112. 
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Culture of adult mouse cardiac myocytes 
Cardiomyocytes from adult mouse hearts were isolated and cultured by modification 
of a previously published protocol (56). Briefly, mice were anesthetized with isofluorane 
and injected with heparin (1.7 IU/g body weight). The heart was rapidly removed and 
perfused through the ascending aorta for 4 min with perfusion buffer (120 mM NaCl, 15 
mM KCI, 0.6mM KH2P04, 0.6mM NaH2P04, 1.2mM MgS04, lOmM HEPES, 30mM 
Taurine, lOmM 2,3-butanedione monoxime, and 5.5mM glucose, pH 6.95). After 4 min, 
the perfusion was switched to perfusion buffer supplemented with collagenase II 
500U/ml perfusion buffer (Worthington, NJ) )for 8-11 minutes. The ventricles were then 
teased into 10-12 small pieces in stop buffer (perfusion buffer with 10% bovine calf 
serum and 12.5f..lM calcium) and transferred to a 15ml conical tube. Tissue was further 
dissociated by pipetting and myocytes were allowed to sediment by gravity for 10 
minutes. After removal of supernatant, the pellet was carefully suspended in stop buffer. 
Calcium was reintroduced in three steps at room temperature to reach a final 
concentration of 1.2 mM. Isolated ventricular myocytes were plated at a density of 50 
rod-shaped myocytes per square millimeter on laminin-coated cover slips in 10cm2 
culture tubes (TPP, Switzerland) containing plating medium (MEM, 10% bovine calf 
serum, 10mM 2,3-butanedione monoxime, 100Units/ml penicillin, 2mM glutamine and 
2mM NaATP), in 2% CO2, 37°C. Following 1 hr incubation, the plating medium was 
removed and washed once. Myocytes were incubated in 2% CO2, 37°C overnight in 
culture medium (MEM containing 10 ug/ml BSA, 1 unit/ml penicillin and 20 urn 
glutamine with or without 0.4 mM palmitate prebound to 30% fatty acid-free BSA). 
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Measurement of glycolysis and glucose oxidation in cardiacmyocytes 
After 24 hours culture, medium was replaced with new medium containing [5-
3H]glucose (0.25 ~Ci/ml) and [U-14C]glucose(0.15~Ci/ml) in a final volume of2 m!. For 
the no palmitate group, both the old culture medium and assay culture medium did not 
contain palmitate. For the 2 hour palmitate group, overnight culture medium did not 
contain palmitate and assay culture medium contained 0.4 mM palmitate. For 24 hour 
palmitate group, culture medium containing 0.4 mM palmitate and assay culture medium 
did not contain palmitate. For 24 plus 2 hour palmitate group, all culture medium 
contained O.4mM palmitate. The culture tube was sealed with a rubber stopper and a 
plastic central well with a cellulose filter paper and incubated at 37°C for 2 hours. After 
the 2 hr assay incubation, the reaction was stopped by the injection of 70% perchloric 
acid (0.2 ml), which also liberates 14C02 dissolved in the cultured medium. 0.1 ml of 1M 
NaOH was injected into the central well containing filter paper for measuring glucose 
oxidation by quantitative collection of 14C02 released. The culture tube was held at room 
temperature overnight and the central well filter paper was taken for scintillation 
counting. Glycolysis was determined by measuring the production of 3H20 from the [5-
3H]glucose added to the media as previously described (82). The values determined for 
glycolysis and glucose oxidation were normalized to the number of cardiomyocytes to 
yield units of nmollminlcardiomyocyte. 
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Measurement of Fru-2, 6-P2 and Fru-1,6-P2 in adult mouse cardiomyocytes 
For the assay of Fru-2, 6-P2, cardiomyocytes cultured for 24 hours were collected in 
50mM NaOH (80 ul) and kept at 80 DC for 5 min. The cells were cooled and neutralized 
at 4 DC by the addition of ice-cold 1 M acetic acid in the presence of20 mM HEPES. 
After centrifugation at 8,000 g for 10 min, the supernatant was collected and assayed for 
Fru-2, 6-P2 by the PFK-1 activation method (80). For the assay of Fru-2, 6-P2, the buffer 
containing pH8.0 IOOmM TES, 6mM MgCh, 1mM EDTA, O.1mM DTT, 0.22mM 
NADH, 100mM F-6-P, lOmg/ml PPi:PFK-1, aldolase, Glycero-3-phosphate 
Dehydrogenase (GDH) and Triosephosphate isomerase (TIM). The reaction mixtures 
were kept at 30°C for 10 min, then read by spectrophotometer at 340nm wave length. For 
the assay ofFru-1, 6-P2,cardiomyocytes were collected in 1M ice-cold perchloric acid 
(0.1 ml) and centrifuged. The assay was run as previously described (82). 
Active and Total PDC measurement in adult mouse cardiomyocytes 
Active PDH was measured as described essentially as described (92). After overnight 
culture medium was removed and cardiomyocytes in the flask/tube were inserted quickly 
into liquid nitrogen. Cells were collected in homogenization buffer (0.25 ml) containing 
50 mM Hepes, pH 7.5, 0.2 mM KCl, 5 mM dithiothreitol, 0.1 mM Na-p-tosly-L-lysine 
chloromethyl ketone, 0.1 mmolll trypsin inhibitor, 0.02 IU/ml aprotinin, 2% rat serum, 
and 0.25% (v/v) Triton X-lOO; then sonicated forlO seconds by using 10% duty cycle and 
output control of 1 (Branson sonitier 450). Twenty 111 of cell extracts and 20 ul of 
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reaction buffer (50 mM Hepes, pH 7.5,1 mM MgCh, 3 mM NAD, 0.4 mM thiamine 
pyrophosphate, 0.4 mM CoA, 2 mM dithiothreitol, 0.1% TritonX-100, 7.5 D/ml 
lipoamide dehydrogenase, 1 mM pyruvate, and [1_14C] pyruvate (5 /lCi/500ul) were 
added to a plastic cup in a 20 ml scintillation vials sealed with a rubber stopper attached 
to a plastic central well with a cellulose filter paper soaked in 1 N NaOH (0.1 ml) for 
collecting 14C02 . The scintillation vials were incubated at 37°C for 20 min, the reaction 
was stopped by injecting 100 111 of 70% perchloric acid. After incubating at room 
temperature overnight, the central wells containing filter papers were taken for 
scintillation counting. Activity in pmollmin was normalized to cell number. 
Total PDC activity was measured as described by Liu et al. (87). Mg2+ and Ca2+ in this 
method were used to activate the intrinsic cardiomyocyte pyruvate dehydrogenase 
phosphatase activity which converts inactive PDC into active PDC (87, 92). For total 
PDC measurement 45 ul of cell extract from the above preparation were mixed and 
incubated with 5 ul buffer containing 1 mM CaCh, 1 mM of MgCh, and 5 mM 
dicholoroacetate at 30°C for 30 min. The method for measuring total PDC activity was 
the same as used for measuring active PDC as described above. 
Active and Total PDC measurement in adult mouse hearts 
Mice were heparinized and anesthetized with isofluorane (3%). Hearts were rapidly 
cut from the vena cava and freeze-clamped in aluminum blocks pre-cooled in liquid 
nitrogen. Frozen myocardium was powdered under liquid nitrogen and half of the 
myocardium powder was used to measure PDC activity and half used for Western blot. 
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For analysis of the PDC activity, myocardium powder was homogenized for 10 seconds 
in 10 volumes of homogenization buffer using a 10% duty cycle and output control of 1 
with a Branson sonifier 450. After centrifugation at 10,000 g, 4°C for 10 min, the 
supernatant was collected and assayed for active and total PDC activity as above 
described. PDC activity was normalized to protein content. 
Isolation of mitochondria 
Fresh heart tissue was excised and homogenized by a motor driven Teflon pestle 
(Wheaton scientific) in isolation buffer containing 220mM mannitol, 70 mM sucrose and 
5mM MOPS, pH 7.4. The homogenate was centrifuged at 700g, 4°C for 10 min. The 
supernatant was moved to a new tube for centrifuging at 10,000 x g at 4°C for 10 min. 
The mitochondrial pellet was collected and washed again with isolation buffer. 
Western blotting 
Five or ten llg of total protein from freeze-clamped heart, celllysates and 
mitochondrial protein were homogenized with lysis buffer containing 50 mmollL Tris-
HCl (pH 7.5), 5 mmol/L EDTA, 10 mmollL EGTA, 10 Ilg/mL aprotinin, 10 llg/mL 
leupeptin, 10 Ilg/mL pepstatin A, and 50 Ilg/mL phenylmethylsulfonyl fluoride. Tissue 
proteins were collected by centrifuging at 12,000 rpm at 4°C for 10 minutes. The protein 
concentration was determined, and the sample was then mixed with loading buffer (40 
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mmollL Tris-HCl, pH 6.8, 1 % SDS, 50 mmol/L dithiothreitol, 7.5% glycerol, 0.003% 
bromophenol blue) and heated at 95°C for 5 minutes and then subjected to electrophoresis 
on Bis-Tris 4-12% gels (Invitrogen) at 120 V. After electrophoresis of the gel, the 
proteins were transferred to a nitrocellulose membrane in transfer buffer containing 20 
mmol/L Tris, 152 mmollL glycine, and 20% methanol. The membranes were rinsed 
briefly in PBS and blocked in blocking buffer (5% milk and 0.5% BSA) at room 
temperature for 2 hours. The primary antibodies used were anti-PDH-Ela (pSer232) 
rabbit pAb (Calbiochem), PDH-Ela (pSer293) rabbit pAb (Calbiochem), PDH-Ela 
(pSer300) rabbit pAb (Calbiochem), PDH-Ela (E-23) rabbit polyclonal IgG (Santa Cruz 
Biotechnology), MCT2 (M-17) goat polyclonal IgG (Santa Cruz Biotechnology). The 
membranes were incubated with primary antibody overnight. On the second day, 
membranes were then washed 3 times with TBS-T containing 0.05% Tween-20 and 
reacted with secondary antibody for 1 hour. Antigen-antibody complexes were visualized 
by chemiluminescent signal using ECL (Amersham GE healthcare) and quantified using 
TotalLab TL 1 00. Actin expression was used as a control. After detection, the membranes 
were stripped with stripping buffer (50 mmollL Tris-HCl, pH 7.4, with 150 mmollL N aCl 
and 0.1 % B-mercaptoethanol) for 1 hour at room temperature. 
Malate and Oxaloacetate measurement in adult mouse whole hearts 
Hearts from transgenic and control groups were freeze-clamped. Frozen myocardium 
was powdered under liquid nitrogen and homogenized for 30 second in 2 volumes of ice-
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cold 1M percholoric acid. The extract was centrifuged at 13,000 g, 4°C for 15 min. The 
supernatant was collected and was neutralized by the addition of 2M KHC03 (1.05 
volumes ofpercholoric acid). After centrifugation at 13,000 g, 4°C for 10 min, the 
supernatant was collected and assayed for malate and oxaloacetate (45). For the malate 
assay, buffer consisted of 50mM 2-amino-2-methylpropanol buffer pH 9.9, 200uM 
NAD+, pH 9.9, 10mM glutamic acid, 3.5u/ml malate dehydrogenase, 0.411/ml aspartate 
transaminase. The reaction mixtures were kept at room temperature for 5 min, then read 
by spectrophotometer at 340nm. For the oxaloacetate assay buffer of 50mM Tris-HCL 
buffer pH 8.1, 50mM NADH, 0.07u/ml malate dehydrogenase was used. The reaction 
mixtures were kept at room temperature for 5 min, then read by spectrophotometer at 340 
nm wave length. 
Murine in vivo myocardial ischemia-reperfusion and infarct size determination 
Male FVB and Mk mice were subjected to in vivo left coronary artery occlusion and 
reperfusion as described previously(25, 30-33). Briefly, mice were anesthetized with 
intraperitoneal injections ofketamine hydrochloride (50 mg/kg) and sodium pentobarbital 
(50 mg/kg). The animals were then attached to a surgical board with their ventral side up. 
The mice were orally intubated with polyethylene (PE)-90 tubing connected to a Hugo 
Sachs mouse ventilator. The tidal volume and respiratory rate were set for each mouse 
based on body weight and according to standard mammalian allometric equations. The 
mice were supplemented with 100% oxygen via the ventilator side port. Throughout 
anesthesia, body temperature was monitored with a rectal thermometer and held constant 
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between 36-37 degrees Celsius with an infrared heating lamp. A median sternotomy was 
performed using an electric cautery, and the proximal left main coronary artery was 
visualized and completely occluded for 40 minutes with 7-0 silk suture mounted on a 
tapered needle (BV-l, Ethicon). 
At 24 h of reperfusion, the mice were anesthetized as described previously, intubated, 
and connected to a mouse ventilator. A catheter (PE-I 0 tubing) was placed in the 
common carotid artery for Evans blue dye injection. A median sternotomy was 
performed, and the left main coronary artery was re-ligated in the same location as 
before. Evans blue dye (~1.2 ml of a 2% solution) was injected into the carotid artery 
catheter into the heart to delineate the ischemic zone from the nonischemic zone. The 
heart was rapidly excised and serially sectioned perpendicular to the long axis in I-mm-
thick sections, which were then incubated in 1.0% 2,3,5-triphenyltetrazolium chloride for 
five minutes at 37°C to demarcate the viable and nonviable myocardium within the risk 
zone. Each of the five I-mm-thick myocardial slices was weighed. A blinded observer 
assessed the areas of infarct, risk, and nonischemic zone using computer-assisted 
planimetry (Image J, version 1.38x). All of the procedures for area at risk (AAR) and 
infarct size determination have been previously described (30-33). 
Cardiomyocyte responses to hypoxia 
Cardiomyocytes were isolated, and myocyte contractility was measured as previously 
described (90). For the oxygenated assay, myocytes were placed in an open chamber at 
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22°C in HEPES-buffered KH buffer [135 mM NaCl, 4 mM KCl, 1 mM MgCh, 10 mM 
HEPES, 0.33 mM NaH2P04, 10 mM glucose, 10 mM 2,3-butanedione monoxime 
(BDM), and 1.2 mM eaCh; pH 7.4] for 2 h. BDM was included in the contractility assay 
buffer because it preserves rod-shaped myocytes during metabolic inhibition (37). We 
(89)have previously described the use ofBDM during hypoxic assays of myocyte 
contractility. For hypoxia, cardiomyocytes were perfused in the same buffer saturated 
with N2 for 15 min and maintained and assayed in a sealed chamber for 2 h at 22°C. 
Myocytes were stimulated at 1 Hz using platinum electrodes attached to the chamber. 
The mechanical properties of ventricular myocytes were assessed using a video-based 
edge detection system (lonOptix, Milton, MA) as previously described (90). Cell 
shortening and re-lengthening were assessed using the following indexes: peak 
shortening, time to 90% re-lengthening, and maximal velocities of shortening and re-
lengthening (±dL/dt). 
Histological Study 
Collagen accumulation in the heart sections was determined as described previously 
(2). Five J.lm heart sections were placed on slides, deparaffinized, and incubated with a 
saturated solution of picric acid containing 0.1 % Sirius Red for staining collagen and 
0.1 % Fast Green which stains noncollagen proteins. Sections were kept in the dark and 
incubated for 30 min. They were then rinsed with distilled water, dehydrated and 
mounted with permount. The sections were visualized, photographed and the interstitial 
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fibrosis was quantified by a blind observer using a scale of 0-2 based on the severity of 
the collagen accumulation, as we previously described (17). The section was given a 
score of 0 for mild accumulation, 1 for moderate accumulation, and 2 for severe 
accumulation. 
Quantitative RT-PCR 
RNA expression of cardiac pathological markers brain natriuretic peptide (BNP) and 
B-MHC was measured by real-time quantitative PCR using an ABI 7300 instrument 
(Applied Biosystems, Foster City, CA) with a modified protocol (9). In brief, total RNA 
was purified from the frozen heart and reverse transcribed to cDNA. RNA-derived 
cDNA (10 ng) was mixed with Taqman universal PCR Master Mix and the appropriate 
primers and probe and run at 50°C for 2 min, 95°C for 10 min, and 95°C for 15 s 
followed by 60°C for 1 min for 40 cycles. The assay identification numbers for the 
specific primers and probe of each gene were Mm01255779 _gl for BNP and 
Mm00600555_ml for B-MHC (Applied Biosystems). The results for B-MHC and BNP 
were nonnalized to ND4 mRNA level. 
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Statistical analysis 
Two factor comparisons were analyzed by two-way ANOVA and Student Newman-
Keuls post hoc test. Single comparisons were performed by paired or unpaired Student's 
t-test. The accepted level of significance was 0.05. Statistical analyses were performed 




Transgenic mice were generated with the transgene Mk, which contained a kinase-
activelbisphosphatase deficient mutant ofliver PFK-2 (85) regulated by the cardiac 
specific ~-MHC promoter (22). Six lines ofMk transgenic mice were generated on a 
FVB background and were designated as lines Mkl to Mk6. The founders of lines 1, 2, 4, 
and 5 produced litters. Western blots with antibody made against liver PFK-2 (Fig. 4) 
demonstrated obvious overexpression of the trans gene in Mk mouse hearts. To confirm 
the increase in PFK-2 activity, we measured the level of Fru-2, 6-P2 in transgenic and 
control hearts. Cardiac Fru-2, 6-P2 was elevated by three- to fourfold in all transgenic 
lines (Fig. 5). Mkl and Mk2 mice were produced first and had indistinguishable 
phenotypes for gene expression and Fru-2, 6-P2 1evels, and they were used 
interchangeably in experiments concerning phenotype. 
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Cardiac metabolite concentrations 
By modifying PFK activity, the Mk transgene is expected to alter the concentration of 
metabolites of the glycolytic pathway. Levels of several metabolites were measured in 
flash-frozen hearts from FVB and Mk transgenic mice that had been fasted for 3 h. Table 
1 shows these results. G6P was reduced by ~ 1.6 fold in Mk transgenic hearts. Coincident 
with the reduction in G6P levels, glycogen was decreased by more than eightfold in Mk 
hearts. Two metabolites downstream of PFK, Fru-l, 6-P2 and pyruvate, were increased in 
concentration; however, the increase did not reach statistical significance. Fru-l,6-P2 was 
measured as the combined pool of Fru-l ,6-P2, dihydroxyacetone phosphate, and 
glyceraldehyde-3-phosphate since these metabolites are in equilibrium and are most 
accurately measured together (45). 
Effect of kinase-active PFK-2 on cardiac metabolism 
The effect of the Mk trans gene on glycolysis was assessed in Langendroff-perfused 
hearts by measuring the metabolism of 5-tritiated glucose. The release of tritiated water 
measures the glycolytic steps through the triose phosphate isomerase reaction. The 
amount of lactate produced during the perfusion was also measured. As shown in Figure 
6, in both the presence and absence of palmitate, the release of tritiated water and lactate 
were significantly elevated in Mk transgenic hearts compared with control hearts. The 
Mk effect on glycolysis was evident both before and after the addition of insulin. The 
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increase in glycolysis did not appear to be related to contractility or perfusion pressure 
since no significant differences were observed for contractility between transgenic and 
control hearts at any time point (data not shown). Also, in both groups, the perfusion 
pressure averaged 65 mm Hg while the flow rate was maintained at 2 mllmin. To 
determine if the trans gene altered the effect of palmitate and insulin, the results for 
tritiated water release were replotted in Figure 5. Before the addition of insulin, we found 
palmitate to be a more potent inhibitor of glycolysis in FVB mice (55% inhibition) than 
in Mk mice (18% inhibition). In the presence of insulin, palmitate did not reduce 
glycolysis in FVB or Mk hearts. Our laboratory (17) has previously reported that a 
transgene that reduced cardiac Fru-2, 6-P2 blunted the insulin response in perfused hearts. 
However, the present study (Figure 7, C and D) failed to support the converse: compared 
with FVB hearts, there was no increase in the insulin response in Mk hearts with 
increased Fru-2, 6-P2. In the absence of palmitate, insulin increased glycolysis by 39% 
and 31 %, respectively, in FVB and Mk hearts. In the presence of palmitate, the insulin 
response was markedly increased, by 230% of basal in FVB mice and by 93% of basal in 
Mk hearts. The very large insulin response in palmitate-perfused FVB hearts was due 
primarily to the potent inhibition of basal glycolysis by palmitate (Fig. 7A), which was 
eliminated by the addition of insulin. Folmes et al. (20) have also reported that insulin has 
a greater effect on glycolysis in the presence of palmitate. In addition to the Mk-induced 
increase in glycolysis, we found a 30-50% significant reduction in palmitate oxidation in 
Mk hearts that was true throughout the duration of the perfusion (Fig. 8A). Insulin 
produced a significant reduction (P =0.01 by paired t-test) in palmitate oxidation in both 
FVB and Mk hearts. The average decrease produced by insulin was 32 ±1 % and 42 ± 6% 
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for FVB and Mk hearts, respectively (Fig. 8B), which was not significantly different in 
the two types of hearts (FVB vs. Mk, P = 0.13). 
Efficacy of the Mk trans gene in cultured cardiomyocytes 
To confirm that the Mk transgene in cultured cardiomyocytes retained the activity we 
found in whole heart, the products ofPFK1 and PFK2 were measured. As shown in 
Figure 9 and Figure 10, Fru-2, 6-P2 was 2.8 fold higher in Mk myocytes compared to 
FVB myocytes and Fru-1, 6-P2 was increased by 1.7 fold. This demonstrates that the 
trans gene was still effective in 24 hr cultured cardiomyocytes. 
Glycolysis, glucose oxidation and effect of palmitate on glycolysis and glucose 
oxidation in cultured adult mouse cardiac myocytes 
Glycolysis and glucose oxidation were measured in cardiomyocytes to test the effect 
of elevated Fru 2,6P2 on cardiomycoyte metabolism and to assess how it interacted with 
the effect of palmitate. Figure 11 shows the results for glycolysis. Mk myocytes had 
significantly higher rates of glycolysis than FVB myocytes in the presence or absence of 
palmitate and palmitate had similar inhibitory effects on glycolysis in transgenic and 
control myocytes. To reduce glycolysis required the 24 hour pre-assay exposure to 
palmitate, no inhibition was seen if palmitate was present only during the 2 hour assay. 
Figure 12 shows the glucose oxidation rates measured in the same myocyte cultures. Mk 
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myocytes had higher rates of glucose oxidation than FVB myocytes except under the No 
Palmitate condition when palmitate was absent before and during the oxidation assay. 
Palmitate inhibited glucose oxidation in transgenic and control myocytes under all 
treatement conditions. Unlike glycolysis, palmitate inhibited glucose oxidation even if it 
was not present during the 24 hr culture period. 
PDC activity in Mk hearts and cardiomyocytes 
Pyruvate dehydrogenase complex (PDC) activity is generally rate limiting for 
mitochondrial glucose oxidation. PDC activity was measured to determine if it could 
account for the increase found in cardiomyocyte glucose oxidation. Unexpectedly, both 
active PDC (PDCa) and total PDC activity (PDCt) were significantly (P<O.OI) reduced in 
Mk compared to FVB cardiomyocytes (Figure 13). Mk PDCa activity was reduced by 
59% without palmitate and 37% with palmitate. Mk PDCt activity was reduced by 46% 
without palmitate and 52% with palmitate. 
To be sure that the Mk decrease in PDCa and PDCt activity was not an artifact of 
cardiomyocytes isolation or culture conditions, PDCa and PDCt was measured in whole 
hearts. As shown in Figure 14 PDCa activity and PDCt activity were significantly 
(P<O.OI) reduced in Mk transgenic hearts compared to FVB hearts. The magnitude of the 
whole heart Mk reduction was approximately 20% for PDCa and PDCt. 
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PDC E 1 a in cardiomyocytes and whole hearts 
Western blots were used to measure the amount and phosphorylation state of PDC 
subunit Eia (Figure 15A) in cardiomyocytes. Consistent with the reduction PDCt 
activity, the abundance ofPDC E1a was reduced by 52% in Mk cardiomyocytes. The 
activity of PDC is acutely controlled by reversible phosphorylation of 3 serine residues 
on the E 1 a subunit. Western blots using antibodies specific for different phosphorylation 
sites on PDC E 1 a revealed a two-fold increase in E 1 a PSer 293 but no apparent change 
in the levels ofEla PSer 232 or PSer 300. However, when levels of phosphorylated 
forms ofPDC E1a were normalized to total Eia protein both PSer 293 and PSer 300 
were significantly increased compared to FVB (Figure 15C). 
Western blots of whole heart protein produced similar, though more modest 
differences between Mk and FVB samples (Figure 16). In Mk heart E1a protein was 
significantly reduced and E1a PSer 293 was significantly increased. Normalized to the 
amount ofEla content, PSer 293 and PSer 232 were significantly elevated in Mk heart. 
Alternative pathways for glucose oxidation 
Elevated glucose oxidation despite reduced PDC activity indicated that Mk myocytes 
must have other means for entry of glycolytic products into the mitochondria and citric 
acid cycle. One proposed mechanism, independent of PDC, for lactate or pyruvate entry 
into mitochondria is via the moncarboxylate transporter (MCT). MCTs have been 
identified on mitochondria of many tissues including heart (12, 24). Our unpublished 
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gene array comparison of Mk and FVB hearts revealed a 70% increase in MCT2 
expression. Based on this suggestive data we isolated mitochondria from Mk and FVB 
hearts and performed a Western blot for MCT2 (Figure 17). The level of MCT-2 in Mk 
mitochondria was significantly increased by 2.15 fold over FVB cardiac mitochondria. 
Multiple anaplerotic pathways exist for glucose oxidation including conversion of 
pyruvate to malate via malic enzyme and conversion of pyruvate to oxaloacetate via 
pyruvate carboxylase. As shown in Figure 18 malate content was significantly increased 
by 84% in Mk hearts, whereas oxaloacetate was the same in FVB and Mk hearts (Figure 
19). Since Pound et aI., (65) showed that malate is increased in hearts with elevated 
anaplerosis via malic enzyme our results are at least suggestive of increased analplerosis 
via malate in Mk hearts. 
Myocyte Contractility in Hypoxia 
To determine the effect of increased glycolysis on cardiomyocyte contractility and 
response to hypoxia in Mk transgenic hearts, myocytes were isolated from Mk and FVB 
hearts and incubated with oxygenated or nitrogen bubbled Krebs buffer. Myocyte 
contractility was measured using video based edge detection system and the results are 
shown in figure 20. Under normoxic condition there was no significant difference in 
contractility between Mk and FVB myocytes, as assessed by ±dlldt and % peak 
shortening. However, under hypoxic condition, Mk myocytes showed significantly 
increased contractility compared with FVB control myocytes for all three parameters. In 
FVB myocytes hypoxia reduced all of the variables of contractility by twenty to over 
31 
thirty percent, but in Mk myotyes hypoxia had a zero to ten percent effect. These results 
indicate that the Mk trans gene provided almost complete protection from hypoxia-
induced contractile deficits in our culture conditions. 
Myocardial infarct size 
In order to establish whether the cytoprotective effects associated with Mk 
transgenesis in isolated myocytes extended to the in vivo setting, we subjected FVB and 
Mk mice to experimental myocardial infarction. As shown in Figure 21, the areas-at-risk 
for infarction with respect to the left ventricular size (AARIL V) were not significantly 
different between FVB (46.3 +/- 3.3%) and Mk (49.3 +/- 6.3%) groups. Infarct size 
expressed relative to the AAR (lNF/AAR) was also not different between FVB (28.7 +/-
5.1 %) and Mk (26.2 +/- 4.8%). Likewise, the INF expressed relative to the entire LV 
(lNF/LV) was not different between FVB (13.5 +/- 2.8%) and Mk (12.8 +/- 2.8%). 
Cardiac Hypertrophy in Transgenic Hearts 
Despite the fact that the Mk trans gene was beneficial to hypoxic cardiomyocyte 
function we noted an increase in cardiac size. We found that heart weight and heart to 
body weight ratio were significantly increased by ~ 17% compared to FVB control mice, 
whereas body weights were similar between Mk mice and FVB mice (Table 2). To 
determine if this corresponded to a change in cardiomyocyte size we also compared 
isolated cardiomyocyte length (right column of Table 2), measured using video based 
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edge detection. Cardiomyocyte length in Mk transgenic hearts was significantly longer 
than that in FVB hearts. The cardiac hypertrophy raised the possibility that elevated 
glycolysis was detrimental to the heart. Expression of two markers of cardiac stress, ~­
MHC and BNP were unchanged (Figure 22 and 23) and H&E staining (Figure 24) ofMk 
hearts appeared normal. However, sirius red staining for fibrosis appeared to be 
consistently increased in Mk hearts (Figure 25A) and this was confirmed by semi-
quantitative analysis (Figure 25B). 
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DISCUSSION 
Lipid metabolism provides most energy for cardiac contraction but under some 
pathological conditions such as hypertrophy and ischemia-reperfusion (2), glucose 
metabolism increases. It is not clear whether this increase in glucose metabolism is a 
beneficial, adaptive response of the heart or a detrimental, maladaptive response. To 
avoid the effect of cardiac pathology investigators have employed overexpression of 
glucose transporters in the heart to increase glycolysis. Belke et al (7) found that 
overexpression of human GLUT4 inceased glycolysis but this did not increase glucose 
oxidation. On the other hand cardiac overexpression of GLUT 1 (43,46) increased both 
glycolysis and glucose oxidation. 
Mk transgenic mice 
In the current experiments, we developed transgenic mice designed to have a specific 
and permanent increase in cardiac glycolysis, independent of hypertrophy or ischemia. 
Multiple lines of mice were produced with a cardiac specific, bisphosphatase deficient 
mutant of the enzyme PFK2, designated trans gene Mk. The trans gene produced a three 
to four fold increase in cardiac levels of Fru-2, 6-P2, which is a potent stimulator ofthe 
glycolytic regulatory enzyme, PFKl. In this study, we show multiple effects of the 
transgene. It increased glycolysis and glucose oxidation but reduced total and active PDC 
activity. Despite depletion of available PDC, coupling between glycolysis and glucose 
oxidation was maintained possibly via anaplerosis through malate. The Mk trans gene 
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reduced palmitate oxidation, and made glycolysis less susceptible to inhibition by 
palmitate. The trans gene markedly improved myocyte contractility during hypoxia, but it 
did not alter infarct size in response to ischemia in vivo. Despite some beneficial actions, 
the Mk transgene promoted hypertrophy and cardiac fibrosis. 
For effects produced by the Mk trans gene to provide relevant information about the 
role of Fru-2, 6-P2 in cardiac pathology, it is important that the increase in Fru-2, 6-P2 
concentration in Mk transgenic hearts be similar to the concentrations achieved in known 
conditions of cardiac pathology. Pressure over-load hypertrophy induces a 2-6 fold 
increase in Fru-2, 6-P2 (6, 51). Anoxia or ischemia results in a 2-3 fold elevation in 
cardiac Fru-2, 6-P2 content (49). And stimulation of isolated cardiomyocytes with insulin 
produces a 4-fold increase in Fru-2, 6-P2 content (39). Thus the three to four fold 
increase in Fru-2, 6-P2 seen in our transgenic mice is similar to the increases produced by 
insulin, hypertrophy, anoxia or ischemia in the heart (6,39,49,51) 
Mk effects on glycolytic metabolism in vivo 
An elevation in Fru-2, 6-P2 levels should stimulate activity ofPFK-l. If this is true, 
glycolytic metabolites upstream ofPFK-l should be reduced and metabolites downstream 
of PFK-l should be increased in transgenic hearts. Our data showed that the 
concentration of Glc-6-P was significantly reduced by 1.6 fold. This reduction was likely 
the result of increased disposal of Fru-6-P by greater flux through PFK-l, creating a drain 
on G1c-6-P concentrations. Glycogen, the production of which branches offupstream of 
PFK-l, was diminished almost nine fold in transgenic hearts. The large magnitude of the 
glycogen effect may be due to the fact that Glc-6-P has two roles in the control of 
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glycogen content: Glc-6-P is a substrate for glycogen production and Glc-6-P is a 
positive regulator of glycogen synthase (54). In addition the increased PFK-l activity 
promotes greater use of glycogen to fuel glycolysis. The expected increase in metabolites 
downstream ofPFKl was not as clear as the decrease in upstream metabolites. The 
concentrations of Fru-l, 6-P2 and pyruvate increased 50 - 70 %, but the changes were not 
statistically significant. This smaller downstream effect may reflect cardiac adaptation to 
increased PFK-l flux. This could be due to greater lactate disposal, as we saw in 
perfused transgenic hearts, or to greater mitochondrial oxidation of pyruvate obtained 
from glucose (32, 33, 35, 37, 54). 
The conversion ofF6P to Fru-I, 6-P2 by PFK is one of the rate-limiting, regulated 
steps of cardiac glycolysis. Therefore, we anticipated an increase of glycolytic flux in 
perfused Mk hearts. Even in the absence of lipid, glycolytic flux in Langendorff perfused 
Mk hearts was consistently 20% higher than in nontransgenic hearts. This was not 
secondary to elevated contractility or to altered coronary vascular resistance since we 
detected no effect of the trans gene on these variables. The most likely cause was the 
increased activity of PFK. These results support a significant role for Fru-2,6-P2 even in 
the absence of lipid. The addition of 0.4 mM palmitate to the perfusate produced an 
apparent two-fold increase in the impact of the transgene on glycolytic flux. This was 
because palmitate depressed glycolysis less in Mk hearts than in FVB control hearts. 
Fatty acids inhibit glycolysis in large part by inhibiting PFK via the PFK inhibitors citrate 
and ATP. Fru-2, 6-P2 antagonizes this inhibition (27). In addition, we found that 
palmitate oxidation was about twofold lower in Mk hearts; consequently, palmitate 
perfusion produced less citrate and ATP in Mk hearts than in FVB hearts. Therefore, we 
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suggest that a combination of elevated Fru-2, 6-P2 and reduced production of citrate and 
A TP minimized the effect of fatty acids to inhibit glycolysis in Mk hearts. 
Mk effects on glycolysis and glucose oxidation in cultured cardiomyocytes 
To investigate in vitro metabolism changes in Mk mice, primary cultured adult 
cardiomyocytes were used. The level of Fru-2,6-P2 was increased by 2.8 fold in Mk 
cardiomyocytes compared to FVB myocytes, which was consistent with increased Fru-
2,6-P2 in Mk whole heart and in concert, the level of Fru-l,6-P2 was also significantly 
increased by 73% in Mk cardiomyocytes. 
With increased Fru-2, 6-P2, glycolysis in Mk cardiomyocytes increased by 40% in the 
both the presence and absence of palmitate and glucose oxidation was significantly 
increased by 37%-62% in Mk myocytes in the presence of palmitate. In the absence of 
palmitate, glucose oxidation had no significant difference between MK group and FVB 
group. The Randle cycle illustrates that there is a competition between glucose and 
palmitate for their oxidation. Overexpression of GLUT 1 trans gene (43, 46) increased 
glucose oxidation and decreased fatty acid oxidation. Cardiac specific overexpressed 
human GLUT4 (7) in mouse led to increase glycolysis but not in glucose or fatty acid 
oxidation. 
In hypertrophied heart, the coupling of glycolysis and glucose oxidation becomes 
disrupted by a not fully delineated mechanism (40). However, increased glycolysis was 
coupled with increased glucose oxidation in our Mk cardiomyocytes. We expected an 
increase in PDC activity in our Mk transgenic hearts, because PDC, an important 
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regulator for glucose oxidation, links glycolysis to TCA cycle by catalyzing the 
irreversible oxidative decarboxylation of pyruvate to acetyl-CoA, C02 and NADH. 
However, unexpectedly, both active and total PDC activities were decreased. One human 
study (23) shows that activity ofPDC was decreased in muscle, heart and liver but was 
normal in skin fibroblasts. Furthermore, other studies support the finding of changes of 
PDH activity and content. A mild hypertrophied heart induced by five weeks of pressure 
overload exhibits a decrease of PDC activity (70) and a failing heart with higher glucose 
oxidation and lower fatty acid oxidation induced by 3 weeks of pacing shows a reduction 
ofPDH-E2 mRNA and protein, although with normal PDC activity (65). Currently there 
are no clear mechanisms to explain the decrease PDC activity. However, an islet study 
demonstrated that accumulation oflong chain acyl-CoA can inhibit PDC activity (44). In 
Mk hearts, both fatty acid oxidation and NADPH content (data not shown here) were 
reduced, suggesting long chain acyl-CoA may be accumulated in Mk heart to inhibit PDC 
activity. Metabolic acidosis show pyruvate oxidation in both liver and human skeletal 
muscle during exercise by deceasing activity of PDC (26, 77). Reduced PDC activity 
results from alterations in the content ofPDC substrates, acetyl-CoA, NADH and H+, 
leading to greater relative activity of PDK (26). In our Mk hearts, lactate production was 
about 2 fold higher compared to control group, suggesting lactic acidosis may stimulate 
PDK activity contributing to decrease of PDC activity by phosphorylation or accelerating 
PDH protein degradation. Other factors e.g. HNE (28) and TNF-a (91) could also be 
possible reasons involved in the pathogenesis of decreased PDC activity in Mk hearts. 
The paradoxical findings between PDC activity and glucose oxidation in these studies 
suggested that PDC did not playa primary role or directly relate with alteration of 
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glucose oxidation. PDC is responsible for the pyruvate decarboxylation which accounted 
for about 42% of citrate. Since entry of pyruvate into the TCA cycle through PDC is 
disrupted in Mk hearts, alternative routes for pyruvate influx to the TCA cycle have been 
proposed. Isolated perfused heart experiments (62) showed that pyruvate can be 
carboxylated to form malate or oxaloacetate (OAA) via malic enzyme or pyruvate 
carboxylase (Figure 2). In Mk hearts, malate content increased by 84%, although the 
OAA content was not changed between Mk and FVB. MCT-2, a pyruvate and lactate 
transporter was increased by about 70% in mRNA level and elevated by 2 fold in protein 
level in mitochondria, suggesting an increased flux of pyruvate into the mitochondria for 
OAA production through pyruvate carboxylase and an increased flux of malate via malic 
enzyme into mitochondria. High rate of citric acid cycle flux with low concentration of 
intermediates (55) may explain the lack of change of OAA content despite the increase of 
MCT-2 protein in mitochondria. Furthermore, in isolated rat heart, studies show that 
malic enzyme but not pyruvate carboxylase predominates in the heart (62). Thus, 
elevation of malate content by about 84% in Mk transgenic hearts might indicate a major 
anaplerosis pathway for increasing citric acid cycle flux, although both malic enzyme and 
PC are constitutive processes in the heart. 
Functional and morphological effects of the Mk trans gene 
Basal contractility was unchanged in Mk hearts when assayed either during 
Langendorff perfusion or in isolated cardiomyocytes. This is consistent with results we 
have obtained with two other transgenic models of increased or decreased glycolysis (17, 
42). The results from all of these transgenic lines have shown that altering glycolysis for 
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many months does not change myocyte contractility when assayed in oxygenated 
conditions. During hypoxia, glycolysis becomes more important to myocyte function. 
Consistent with this, cultured Mk myocytes were much less susceptible to hypoxia. In 
fact, under hypoxic conditions that significantly impaired control myocytes in our assays, 
we saw no detectable decline in Mk cardiomyocyte contractility. Resistance to hypoxia is 
the opposite of what we previously found in myocytes with impaired glycolytic capacity 
(17). This confirms the essential role of glycolysis during hypoxic conditions. However, 
isolated myocyte experiments do not allow for extrapolation to in vivo conditions. In 
vivo, multiple fuel substrates are available, in contrast to the sole substrate of glucose 
used for in vitro myocyte culture. Also, excess lactate (Figure 3) from increased 
glycolysis in Mk hearts may accumulate in poorly perfused myocardium of ischemic 
intact hearts (68). In addition, fibrosis and hypertrophy in Mk mice could increase cardiac 
work during in vivo ischemia, and the reduced glycogen content (Table 1) of Mk hearts 
reduced carbohydrate reserves. Therefore, it was not a complete surprise that the 
protection from hypoxia in isolated myocytes was not replicated in vivo, where infarct 
damage following ischemia- reperfusion was similar in transgenic and control hearts. A 
more complete analysis of ischemia resistance in Mk hearts should be undertaken using 
low-flow and stop-flow perfusion of isolated hearts to distinguish what components 
contribute to resistance to hypoxia of cardiomyocytes in culture but not in vivo. 
Despite increased glycolysis by which the Mk trans gene can protect cardiomyocytes 
against hypoxia, we found there is an increase in cardiac size. Heart weight, heart weight-
to-body weight ratio, and cardiomyocyte length were all significantly elevated in Mk 
transgenic mice, demonstrating hypertrophy. To test if this mild hypertrophy indicated 
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cardiac pathology, we examined two other signs of pathology: upregulation of "fetal state 
cardiac genes" (53,54) and induction of fibrosis. There was no significant effect of the 
Mk transgene on the expression of~-MHC and BNP. Since these genes are upregulated 
by stress, this did not support the conclusion that Mk hearts were undergoing severe 
pathological stress (63). On the other hand, we found that cardiac fibrosis was increased, 
and fibrosis is a cardiac stress marker (9). Overall, the weight of the evidence, fibrosis 
and hypertrophy imply that the Mk transgene induces a mild state of pathology. By 
constitutively elevating Fru-2,6-P2, the Mk trans gene chronically elevated glycolysis and 
blocked the normal mechanisms controlling carbohydrate usage. The increased glycolysis 
of chronic heart failure may ultimately be maladaptive. It is striking that our present 
transgene, which elevated Fru-2, 6-P2, and our previous transgene (17), which reduced 
Fru-2, 6-P2, both produced mild hypertrophy and fibrosis. This demonstrates the 
sensitivity of the heart to disruption of normal metabolic control. 
Relevance to diabetic cardiomyopathy 
In diabetes the metabolism of the heart becomes much more dependent on fatty acids 
and simultaneously the rate of glycolysis and glucose oxidation goes down. This change 
in fuel usage may be one of the causes of diabetic cardiomyopathy. Our Mk mice 
represent the opposite situation to diabetes: Glycolysis and glucose oxidation are elevated 
and fat usage is reduced. Since the Mk mice had mild cardiac pathology this result 
suggests that a reversal of diabetic cardiac fuel usage would not necessarily be good for 
the heart. Both diabetic cardiomyopathy and Mk cardiac pathology suggest that 
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maintaining the metabolic flexibility of the heart to use the most appropriate or available 
fuel substrate is essential to avoiding cardiac dysfunction. 
Summary 
In summary, we produced mice with chronic and stable elevation of cardiac Fru-2, 6-
P2. This resulted in significant changes in cardiac metabolite concentrations, increased 
glycolysis and glucose oxidation, reduced palmitate oxidation, elevation of malate 
content and decreased PDC activity without uncoupling the glycolysis and glucose 
oxidation and protection of isolated myocytes from hypoxia. Increased malate content 
suggested that increased anaplerosis pathway in Mk hearts solved the paradoxical finding 
between reduced PDC activity and elevated glucose oxidation. This increased anaplerosis 
pathway could be associated with the pathological changes of hypertrophy with cardiac 
fibrosis in Mk heart. Finally, chronic elevation of glycolysis produced detrimental effects, 
suggesting that the elevation of glycolysis in failing hearts could be injurious to an 














Figure 1: A balance between glucose and fat consumption exists in the 
cardiomyocyte from normal heart. Glucose is transported into cytosol by glucose 
transporter I and 4 and provides 30% of energy for heart through glycolysis and glucose 
oxidation as shown in the left pathway. Fatty acid is transported into cytosol by 
transporters FAT /CD36 etc. for fatty acid oxidation and provides 70% energy for heart as 





Figure 2: Alternative routes for pyruvate influx from glucose to the citric acid cycle 
(anaplerosis). The major route for pyruvate to enter the citric acid cycle is by conversion 
to acetyl-CoA by the pyruvate dehydrogenase complex (PDC). There are also two 
anaplerotic pathways shown for entry of pyruvate into the citric acid cycle. Cytosolic 
pyruvate carboxylation to malate via malic enzyme (ME) or mitochondrial carboxylation 
to oxaloacetate via pyruvate carboxylase (PC). MCT -2 can transport pyruvate or lactate 
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Figure 3: Scheme for potential beneficial and detrimental effects of high glycolysis 




Figure 4. Transgenic hearts overexpress 6-phosphofructo-2kinase/fructose-2,6-
bisphosphatase (PFK-2) protein For the Western blot, cardiac protein was analyzed 
using rabbit anti-rat liver PFK-2 antibody. Extracts from 3 Mkl hearts are shown. Similar 
results were obtained in all Mk transgenic lines. 
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Figure 5. Transgenic hearts have elevated fructose-2,6-bisphosphate(Fru-2,6-Pz}. 
For the measurement of Fru-2, 6-P2, hearts were extracted with 50 mM NaOH and Fru-2, 
6-P2 was estimated using pyrophosphate-dependent fructose-6-phosphate 1 
phosphotransferase. Transgenic Fru-2, 6-P2 values were significantly higher than those in 
FVB hearts (* P < 0.01 by ANOVA). No significant differences were obtained within Mk 
groups. The numbers of animals used were 4 FVB, 4 Mkl, 4 Mk2, and 3 Mk5 mice. 
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TABLE 1 Glc-6·P Fru·1,6,Pl Fru·2,6,Pl Pyruvate Glycogen 
Inmollg) Ilnmollg) Inmollg) Inmollg) lumollg) 
FVB 225±67 277±93 5,12±O,88 133±44 2,4±1,94 
Mk 140±17 356±108 10,4±1.34 227±110 O,27±o,22 
Pvalue 0,01 0,25 0,01 0,15 0,01 
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Table 1: Glycolytic intermediates concentration in FVB and Mk hearts. Values 
are means ± SE for at least 5 mice in each group after a 3 hr fast. P values were 
determined by students t-test. . G6P was reduced by ~ 1.6 fold in Mk transgenic hearts 
(p<O.OI). Coincident with the reduction in G6P levels, glycogen was decreased by more 
than eightfold in Mk hearts (p<O.Ol). Two metabolites downstream ofPFK, Fru-I, 6-P2 
and pyruvate, were increased in concentration; however, the increase did not reach 
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Figure 6: The kinase active PFK-2 transgene increases glycolysis in Langendorff 
perfused hearts. A and C: glycolysis (A) and lactate release (C) without palmitate. Band 
D: glycolysis (B) and lactate release (D) in the presence of 0.4 mM palmitate. The shaded 
box shows the addition of200 uU/ml insulin. Values for FVB and Mk hearts were 
compared by two-way ANOVA (* P <0.05).Values are means ± SE for 5 mice/time point. 
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Figure 7. Effect of palmitate and insulin on glycolysis in FVB mice and Mk mice. 
Preinsulin glycolysis was reduced by 55% (* P < 0.02) in FVB mice (A) but only by 18% 
in Mk mice (B; P < 0.24). In the presence of insulin, palmitate did not reduce glycolysis 
in FVB or Mk hearts. C and D: insulin elevated glycolysis in FVB (C) and Mk (D) hearts 
with or without palmitate (#P < 0.02, preinsulin vs. insulin by paired t-test). The relative 
effect of insulin was greater in the presence of palmitate because insulin decreased 
palmitate inhibition of glycolysis. n = 5 FVB and 5 Mk hearts. Data are from Fig. 4 at 30 
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Figure 8. The Mk transgene reduces palmitate oxidation in Langendorff-perfused 
hearts. A: FVB palmitate oxidation values were greater than Mk values at all time points 
(P < 0.01 by two-way ANOVA, n = 5 FVB and 7 Mk hearts). B: effect of insulin on 
palmitate oxidation by replotting the 30- and 80-min results from A. Insulin reduced 






















Figure 9: Levels of Fru-2, 6-P2 in FVB and Mk cardiomyocytes cultured for 24 hrs. 
The * in both panels indicates that each metabolite is higher in Mk cardiomyocytes 
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Figure 10: Levels of Fru-l,6-P2 in FVB and Mk cardiomyocytes cultured for 24 
hrs. The * in both panels indicates that each metabolite is higher in Mk cardiomyocytes 
(P<O.OI by t-test). Values are the mean and standard error of the mean (SEM) for 12 
assays. 
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Figure 11: Measurent of glycolysis in Mk and FVB cardiomyocytes. All myocytes 
were cultured for 24 hrs and then assayed for metabolism during the next 2 hrs. 
Palmitate (O.4mM) was present during the 24 hr culture period and/or the 2 hr assay 
period as indicated on the X axis. * indicates that Mk glycolysis values were 
significantly greater than FVB values measured under the same conditions (P<O.OI). # 
indicates that for FVB myocytes glycolysis values were significantly lower than values 
obtained from FVB myocytes cultured and assayed under the No Palmitate condition 
(Panels A). The symbol & indicates that for the different palmitate conditions Mk 
glycolysis values were significantly lower than values obtained from Mk myocytes 
cultured and assayed under the No Palmitate condition ( P<O.05). The number of animals 
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Figure 12: Measurent of glucose oxidation in Mk and FVB cardiomyocytes. All 
myocytes were cultured for 24 hrs and then assayed for metabolism during the next 2 hrs. 
Palmitate (O.4mM) was present during the 24 hr culture period and/or the 2 hr assay 
period as indicated on the X axis. * indicates that Mk glucose oxidation values were 
significantly greater than FVB values measured under the same conditions (P<O.05). # 
indicates that for FVB myocytes glucose oxidation values were significantly lower than 
values obtained from FVB myocytes cultured and assayed under the No Palmitate 
condition (P<O.Ol). The symbol & indicates that for the different palmitate conditions 
Mk glucose oxidation values were significantly lower than values obtained from Mk 
myocytes cultured and assayed under the No Palmitate condition (P<O.05). The number 
of animals used was 7 FVB and 6 Mk. Statistic were performed by two-way ANOV A. 
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Figure 13: Active PDC and Total PDC activity are decreased in Mk transgenic 
cardomyocytes. PDC activity was measured after 24hr culture with or without O.4mM 
palmitate. Active and total PDC were measured as described in Methods and activity 
was normalized to the number of cells in each culture. * indicates Mk was lower than 
FVB for the same assay and culture conditions (P<O.Ol). # indicates that for FVB 
myocytes active PDC was lower for the palmitate group then the no palmitate group 
(P<O.O 1). The number of animals used was 10 for FVB and 10 for Mk. Statistic were 
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Figure 14: Active PDC and Total PDC activity are decreased in Mk transgenic 
hearts. Active and total POC were measured as described in Methods and activity was 
normalized to the number of cells in each culture. * indicates Mk was lower than FVB 
for the same assay conditions (P<O.O l). The number of animals used was 4 for FVB and 
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Figure 15: PDC Ela expression and phosphorylation in Mk transgenic and FVB 
control cardiomyocytes. (A) Western blots for the indicated antibodies. Each lane 
contains protein from cardiomyocytes isolated from a different Mk or FVB heart. (B) 
Densitometric analysis of protein subunit levels normalized to actin and expressed as % 
of average FVB. (C) Ratio of each PSer normalized to the amount of PDC E I a for that 
sample. * indicates that Mk was significantly different from FVB for the same variable. 
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Figure 16: PDC Ela expresion and phosphorylation in Mk transgenic and FVB 
control hearts. (A) Western blots for the indicated antibodies. Each lane contains 
protein from a different Mk or FVB freeze clamped heart. (B) Densitometric analysis of 
protein subunit levels normalized to actin and expressed as % of average FVB. (C) 
Ratio of each PSer normalized to the amount of PDC E 1 a for that heart. * indicates that 
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Figure 17: Increased amount of MeT -2 in isolated mitochondria from Mk 
transgenic hearts. (A) Immunoblots for MCT2 and COXIV loading control: each lane 
contains mitochondrial protein from a different heart. Arrows indicate positions of MW 
markers MCT2 is 44 kDa and COXIV is 17 kDa. (B) Densitometric analysis of MCT2 
normalized to COXIV expressed in % of the average FVB value. *: Mk is significantly 
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Figure 18. Malate content in whole heart. Metabolites were measured in perchloric 
acid extracts of whole heart as described in Methods. * indicates that malate content was 
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Figure 19. Oxaloacetate content in whole heart. Metabolites were measured in 
perchloric acid extracts of whole heart as described in Methods. Hearts from 7 Mk mice 























Figure 20: Overexpression of kinase-active PFK-2 improves contractility under 
hypoxia. Cardiomyocytes were isolated and incubated under normoxic or hypoxic 
conditions. The contractile properties of ventricular myocytes from FVB control and Mk 
transgenic mouse hearts was measured by video-based edge detection. Graphs show the. 
percentage of shortening under normoxic (A) and hypoxic (B) conditions as well as the 
maximal velocities of cell shortening and relengthening (±dL/dt) under normoxia (C) and 
hypoxia (D). Values are means _ ±SE for 60-80 cells from 4 mice/group. *p < 0.02, Mk 





Figure.21. Myocardial infarct size (INF) was determined after 40 min of in vivo 
coronary occlusion and 24 h of reperfusion. The area at risk (AAR) with respect to the 
left ventricle (LV) was not significantly different between FVB wild-type and Mk 
transgenic mice, indicating consistent execution of the surgical protocol between the two 
groups. The amount of nonviable myocardium, according to triphenyltetrazolium 
negativity, was also similar between the two groups. This was true whether INF was 
expressed relative to the AAR (INF/ AAR) or to the entire LV (INF/LV). P = not 
significant (NS) for all comparisons. n = 6 mice/group. 
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Table myocyte 
2 body wt heart wt length 
sex age (gm) (mg) hw/bw J.lm 
FVB m 138 ± 2 29.9 ± 0.6 132.7 ± 3.3 4.44 ± 0.07 126± 3 
Mk m 131 ± 4 29.8 ± 0.6 155.3 ± 2.5* 5.21 ± 0.08 * 151 ±3 * 
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Table 2. Mk hearts and myocytes are enlarged Values are means ±SE; n = 13 male 
Mk mice and 27 male FVB mice. Myocyte length was the average of 52 myocytes from 4 










Figure 22: Real time-PeR shows no elevation of BNP mRNA in MK transgenic 
mice. Values are the mean ±SE for 4 mice per group. Values were not significantly 










Figure 23: Real time-peR shows no elevation of p-MHC mRNA in MK transgenic 
mice. Values are the mean ±SE for 4 mice per group. Values were not significantly 





Figure 24: H&E staining in Mk and FVB hearts. Cardiac morphology was 
visualized by H&E staining. The above picture shows representative staining of FVB(3) 
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Figure 25: Fibrosis in Mk hearts. Collagen accumulation was visualized by sirius red 
staining at x40. A, shows representative staining ofFVB and Mk hearts. B shows average 
(± SE) score for sirius red staining from 60 photographs taken from FVB (3) and Mk (3) 
mouse hearts. Staining was rated by a blind observer on a scale of 0-2, where 0 indicates 
mild, 1 increased and 2 severe interstitial accumulation of collagen. The values shown 
are means ± SE and were analyzed by student's t-test (*P < 0.01). 
98 
REFERENCES 
1. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, 
Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS, and Kahn 
BB. Cardiac hypertrophy with preserved contractile function after selective deletion of 
GLUT4 from the heart. J Clin Invest 104: 1703-1714, 1999. 
2. Angyalosi G, Neveu R, Wolowczuk I, Delanoye A, Heroo J, Auriault C, and Pancre V. 
HLA class II polymorphism influences onset and severity of pathology in Schistosoma 
mansoni-infected transgenic mice. Infect Immun 69: 5874-5882,2001. 
3. Annane D, Duboc D, Mazoyer B, Merlet P, Fiorelli M, Eymard B, Radvanyi H, Junien 
C, Fardeau M, Gajdos P, and et al. Correlation between decreased myocardial glucose 
phosphorylation and the DNA mutation size in myotonic dystrophy. Circulation 90: 
2629-2634, 1994. 
4. Avogaro A, Nosadini R, Doria A, Fioretto P, Velussi M, Vigorito C, Sacca L, Toffolo 
G, Cobelli C, Trevisan R, and et al. Myocardial metabolism in insulin-deficient diabetic 
humans without coronary artery disease. Am J Physiol258: E606-618, 1990. 
5. Awan MM and Saggerson ED. Malonyl-CoA metabolism in cardiac myocytes and its 
relevance to the control of fatty acid oxidation. Biochem J295 (Pt 1): 61-66, 1993. 
6. Beauloye C, Marsin AS, Bertrand L, Vanoverschelde JL, Rider MH, and Hue L. The 
stimulation of heart glycolysis by increased workload does not require AMP-activated 
protein kinase but a wortmannin-sensitive mechanism. FEBS Lett 531: 324-328, 2002. 
7. Belke DD, Larsen TS, Gibbs EM, and Severson DL. Glucose metabolism in perfused 
mouse hearts overexpressing human GLUT-4 glucose transporter. Am J Physiol 
Endocrinol Metab 280: E420-427, 2001. 
8. Berger M, Hagg S, and Ruderman NB. Glucose metabolism in perfused skeletal 
muscle. Interaction of insulin and exercise on glucose uptake. Biochem J 146: 231-238, 
1975. 
9. Berk BC, Fujiwara K, and Lehoux S. ECM remodeling in hypertensive heart disease. J 
Clin Invest 117: 568-575,2007. 
99 
10. Bernardo BC, Weeks KL, Pretorius L, and McMullen JR. Molecular distinction 
between physiological and pathological cardiac hypertrophy: experimental findings and 
therapeutic strategies. Pharmacol Ther 128: 191-227. 
11. Bishop SP and Altschu1d RA. Increased glycolytic metabolism in cardiac hypertrophy 
and congestive failure. Am J Physiol218: 153-159, 1970. 
12. Brooks GA, Brown MA, Butz CE, Sicurello JP, and Dubouchaud H. Cardiac and 
skeletal muscle mitochondria have a monocarboxylate transporter MCT1. J Appl Physiol 
87: 1713-1718, 1999. 
13. Carlsten A, Hallgren B, Jagenburg R, Svanborg A, and Werko L. Amino acids and 
free fatty acids in plasma in diabetes. II. The myocardial arterio-venous differences 
before and after insulin. Acta Med Scand 179: 631-639, 1966. 
14. Chatham J, Gilbert HF, and Radda GK. Inhibition of glucose phosphorylation by fatty 
acids in the perfused rat heart. FEBS Lett 238: 445-449, 1988. 
15. Chen V, Ianuzzo CD, Fong BC, and Spitzer JJ. The effects of acute and chronic 
diabetes on myocardial metabolism in rats. Diabetes 33: 1078-1084, 1984. 
16. Das 1. Effects of heart work and insulin on glycogen metabolism in the perfused rat 
heart. Am J Physiol224: 7-12, 1973. 
17. Donthi RV, Ye G, Wu C, McClain DA, Lange AJ, and Epstein PN. Cardiac 
expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin 
sensitivity. J BioI Chern 279: 48085-48090, 2004. 
18. Fa1ho1t K, Jensen I, Lindkaer Jensen S, Mortensen H, Volund A, Heding LG, 
Noerskov Petersen P, and Fa1holt W. Carbohydrate and lipid metabolism of skeletal 
muscle in type 2 diabetic patients. Diabet Med 5: 27-31, 1988. 
19. Feuvray D and Lopaschuk GD. Controversies on the sensitivity ofthe diabetic heart 
to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. 
Cardiovasc Res 34: 113-120,1997. 
20. Folmes CD, Clanachan AS, and Lopaschuk GD. Fatty acids attenuate insulin 
regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after 
ischemia. Circ Res 99: 61-68, 2006. 
21. Gibbs EM, Stock JL, McCoid SC, Stukenbrok HA, Pessin JE, Stevenson RW, Milici 
AJ, and McNeish JD. Glycemic improvement in diabetic db/db mice by overexpression 
of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest 95: 1512-
1518, 1995. 
100 
22. Gulick J, Subramaniam A, Neumann J, and Robbins J. Isolation and characterization 
of the mouse cardiac myosin heavy chain genes. J Bioi Chem 266: 9180-9185, 1991. 
23. Hansikova H, Zeman J, Klement P, Technikova-Dobrova Z, Houstkova H, Houstek J, 
and Papa S. Deficiency of pyruvate dehydrogenase complex in tissues of an eight month 
old infant. Biochem Mol Bioi Int 31: 1157-1166, 1993. 
24. Hashimoto T and Brooks GA. Mitochondrial lactate oxidation complex and an 
adaptive role for lactate production. Med Sci Sports Exerc 40: 486-494, 2008. 
25. Hoffmeyer MR, Scalia R, Ross CR, Jones SP, and Lefer DJ. PR-39, a potent 
neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice. Am J 
Physiol Heart Circ Physiol279: H2824-2828, 2000. 
26. Hollidge-Horvat MG, Parolin ML, Wong D, Jones NL, and Heigenhauser GJ. Effect 
of induced metabolic acidosis on human skeletal muscle metabolism during exercise. Am 
J PhysioI277: E647-658, 1999. 
27. Hue L, Beauloye C, Marsin AS, Bertrand L, Horman S, and Rider MH. Insulin and 
ischemia stimulate glycolysis by acting on the same targets through different and 
opposing signaling pathways. J Mol Cell Cardiol34: 1091-1097,2002. 
28. Humphries KM and Szweda LI. Selective inactivation of alpha-ketoglutarate 
dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-
nonenal. Biochemistry 37: 15835-15841, 1998. 
29. Jeremy RW, Ambrosio G, Pike MM, Jacobus WE, and Becker LC. The functional 
recovery of post-ischemic myocardium requires glycolysis during early reperfusion. J 
Mol Cell Cardiol25: 261-276, 1993. 
30. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D, Huang 
PL, and Lefer DJ. Myocardial ischemia-reperfusion injury is exacerbated in absence of 
endothelial cell nitric oxide synthase. Am J Physiol276: H1567-1573, 1999. 
31. Jones SP, Greer 11, Kakkar AK, Ware PD, Turnage RH, Hicks M, van Haperen R, de 
Crom R, Kawashima S, Yokoyama M, and Lefer DJ. Endothelial nitric oxide synthase 
overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ 
Physiol 286: H276-282, 2004. 
32. Jones SP, Hoffmeyer MR, Sharp BR, Ho YS, and Lefer DJ. Role of intracellular 
antioxidant enzymes after in vivo myocardial ischemia and reperfusion. Am J Physiol 
Heart Circ Physiol284: H277-282, 2003. 
33. Jones SP, Zachara NE, Ngoh GA, Hill BG, Teshima Y, Bhatnagar A, Hart GW, and 
Marban E. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. 
Circulation 117: 1172-1182, 2008. 
101 
34. Kagaya Y, Weinberg EO, Ito N, Mochizuki T, Barry WH, and Lorell BH. Glycolytic 
inhibition: effects on diastolic relaxation and intracellular calcium handling in 
hypertrophied rat ventricular myocytes. J Clin Invest 95: 2766-2776, 1995. 
35. Kashiwaya Y, Sato K, Tsuchiya N, Thomas S, Fell DA, Veech RL, and Passonneau 
JV. Control of glucose utilization in working perfused rat heart. J BioI Chern 269: 25502-
25514,1994. 
36. King LM, Boucher F, and Opie LH. Coronary flow and glucose delivery as 
determinants of contracture in the ischemic myocardium. J Mol Cell Cardia I 27 : 701-
no, 1995. 
37. Koyama T, Boston D, Ikenouchi H, and Barry WHo Survival of metabolically 
inhibited ventricular myocytes is enhanced by inhibition of rigor and SR Ca2+ cycling. 
Am J Physiol271: H643-650, 1996. 
38. Kurland IJ, el-Maghrabi MR, Correia JJ, and Pilkis SJ. Rat liver 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase. Properties of phospho- and dephospho- forms and of 
two mutants in which Ser32 has been changed by site-directed mutagenesis. J BioI Chern 
267:4416-4423,1992. 
39. Lefebvre V, Mechin MC, Louckx MP, Rider MH, and Hue L. Signaling pathway 
involved in the activation of heart 6-phosphofructo-2-kinase by insulin. J BioI Chern 271: 
22289-22292, 1996. 
40. Leong HS, Brownsey RW, Kulpa JE, and Allard MF. Glycolysis and pyruvate 
oxidation in cardiac hypertrophy--why so unbalanced? Camp Biochem Physiol A Mol 
Integr Physiol135: 499-513, 2003. 
41. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, and Epstein PN. 
Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51: 174-
181,2002. 
42. Liang Q, Donthi RV, Kralik PM, and Epstein PN. Elevated hexokinase increases 
cardiac glycolysis in transgenic mice. Cardiovasc Res 53: 423-430,2002. 
43. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, and 
Tian R. Cardiac-specific overexpression of GLUT 1 prevents the development of heart 
failure attributable to pressure overload in mice. Circulation 106: 2125-2131, 2002. 
44. Liu YQ, Moibi JA, and Leahy JL. Chronic high glucose lowers pyruvate 
dehydrogenase activity in islets through enhanced production of long chain acyl-CoA: 
prevention of impaired glucose oxidation by enhanced pyruvate recycling through the 
malate-pyruvate shuttle. J BioI Chern 279: 7470-7475,2004. 
45. Lowry JVPOH .. Enzymatic analysis: a practical guide, 1993. 
102 
46. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, and Tian R. Decreased 
contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null 
hearts can be rescued by increasing glucose transport and utilization. Circulation 112: 
2339-2346,2005. 
47. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP, Rodrigues 
B, Popov KM, Harris RA, Brownsey RW, and Allard MF. Pyruvate dehydrogenase and 
the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res 53: 841-
851,2002. 
48. Malhotra R and Brosius FC, 3rd. Glucose uptake and glycolysis reduce hypoxia-
induced apoptosis in cultured neonatal rat cardiac myocytes. J Bioi Chem 274: 12567-
12575, 1999. 
49. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den 
Berghe G, Carling D, and Hue L. Phosphorylation and activation of heart PFK-2 by 
AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Bioi 1 0: 1247-
1255,2000. 
50. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, 
Semigran MJ, Dec GW, and Khaw BA. Apoptosis in myocytes in end-stage heart failure. 
N Engl J Med 335: 1182-1189, 1996. 
51. Nascimben L, Ingwall JS, Lorell BH, Pinz I, Schultz V, Tornheim K, and Tian R. 
Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 44: 
662-667,2004. 
52. Neely JR and Rovetto MJ. Techniques for perfusing isolated rat hearts. Methods 
Enzymol39: 43-60, 1975. 
53. Newsholme EA and Randle PJ. Regulation of glucose uptake by muscle. 7. Effects of 
fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes, starvation, 
hypophysectomy and adrenalectomy, on the concentrations of hexose phosphates, 
nucleotides and inorganic phosphate in perfused rat heart. Biochem J93: 641-651, 1964. 
54. Nielsen IN and Richter EA. Regulation of glycogen synthase in skeletal muscle 
during exercise. Acta Physiol Scand 178: 309-319, 2003. 
55. Nuutinen EM, Peuhkurinen KJ, Pietilainen EP, Hiltunen JK, and Hassinen IE. 
Elimination and replenishment of tricarboxylic acid-cycle intermediates in myocardium. 
Biochem J 194: 867-875, 1981. 
56. O'Connell TD, Rodrigo MC, and Simpson Pc. Isolation and culture of adult mouse 
cardiac myocytes. Methods Mol Bioi 357: 271-296, 2007. 
103 
57. Okar DA, Manzano A, Navarro-Sabate A, Riera L, Bartrons R, and Lange AJ. PFK-
2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. 
Trends Biochem Sci 26: 30-35,2001. 
58. Oldfield GS, Commerford PJ, and Opie LH. Effects of preoperative glucose-insulin-
potassium on myocardial glycogen levels and on complications of mitral valve 
replacement. J Thorac Cardiovasc Surg 91: 874-878, 1986. 
59. Opie LH. Glucose and the metabolism ofischaemic myocardium. Lancet 345: 1520-
1521, 1995. 
60. Owen P, Dennis S, and Opie LH. Glucose flux rate regulates onset of ischemic 
contracture in globally underperfused rat hearts. Circ Res 66: 344-354, 1990. 
61. Palaniswamy C, Mellana WM, Selvaraj DR, and Mohan D. Metabolic Modulation: A 
New Therapeutic Target in Treatment of Heart Failure. Am J Ther. 
62. Panchal AR, Comte B, Huang H, Kerwin T, Darvish A, des Rosiers C, Brunengraber 
H, and Stanley WC. Partitioning of pyruvate between oxidation and anaplerosis in swine 
hearts. Am J Physiol Heart Circ Physiol279: H2390-2398, 2000. 
63. Pandya K, Kim HS, and Smithies o. Fibrosis, not cell size, delineates beta-myosin 
heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl 
A cad Sci USA 103: 16864-16869,2006. 
64. Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 
34: 104-112, 1997. 
65. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, Lanoue KF, Taegtmeyer 
H, O'Donnell JM, and Lewandowski ED. Substrate-enzyme competition attenuates 
upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores 
triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res 
104: 805-812,2009. 
66. Rodrigues B, Cam MC, and McNeill JH. Metabolic disturbances in diabetic 
cardiomyopathy. Mol Cell Biochem 180: 53-57,1998. 
67. Russell RR, 3rd, Yin R, Caplan MJ, Hu X, Ren J, Shulman GI, Sinusas AJ, and 
Young LH. Additive effects ofhyperinsulinemia and ischemia on myocardial GLUTI 
and GLUT4 translocation in vivo. Circulation 98: 2180-2186, 1998. 
68. Sambandam N, Lopaschuk GD, Brownsey RW, and Allard MF. Energy metabolism 
in the hypertrophied heart. Heart Fail Rev 7: 161-173,2002. 
104 
69. Scarabelli TM, Knight R, Stephanou A, Townsend P, Chen-Scarabelli C, Lawrence 
K, Gottlieb R, Latchman D, and Narula J. Clinical implications of apoptosis in ischemic 
myocardium. Curr Probl Cardiol31: 181-264, 2006. 
70. Seymour AM and Chatham JC. The effects of hypertrophy and diabetes on cardiac 
pyruvate dehydrogenase activity. J Mol Cell Cardiol29: 2771-2778, 1997. 
71. Shehadeh A and Regan T J. Cardiac consequences of diabetes mellitus. Clin Cardiol 
18: 301-305,1995. 
72. Stanley WC, Lopaschuk GD, Hall JL, and McCormack JG. Regulation of myocardial 
carbohydrate metabolism under normal and ischaemic conditions. Potential for 
pharmacological interventions. Cardiovasc Res 33: 243-257, 1997. 
73. Stanley WC, Lopaschuk GD, and McCormack JG. Regulation of energy substrate 
metabolism in the diabetic heart. Cardiovasc Res 34: 25-33, 1997. 
74. Stanley WC, Recchia FA, and Lopaschuk GD. Myocardial substrate metabolism in 
the normal and failing heart. Physiol Rev 85: 1093-1129,2005. 
75. Stenbit AE, Tsao TS, Li J, Burcelin R, Geenen DL, Factor SM, Houseknecht K, Katz 
EB, and Charron MJ. GLUT4 heterozygous knockout mice develop muscle insulin 
resistance and diabetes. Nat Med 3: 1096-1101, 1997. 
76. Tian R and Abel ED. Responses ofGLUT4-deficient hearts to ischemia underscore 
the importance of glycolysis. Circulation 103: 2961-2966, 2001. 
77. Toyomizu M, Yamahira S, Shimomura Y, and Akiba Y. Metabolic acidosis inhibits 
pyruvate oxidation in chick liver by decreasing activity of pyruvate dehydrogenase 
complex. Life Sci 65: 37-43,1999. 
78. Ungar I, Gilbert M, Siegel A, Blain JM, and Bing RJ. Studies on myocardial 
metabolism. IV. Myocardial metabolism in diabetes. Am J Med 18: 385-396, 1955. 
79. Van Bilsen M, van Nieuwenhoven FA, and van der Vusse GJ. Metabolic remodelling 
of the failing heart: beneficial or detrimental? Cardiovasc Res 81: 420-428, 2009. 
80. Van Schaftingen E, Lederer B, Bartrons R, and Hers HG. A kinetic study of 
pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application 
to a microassay of fructose 2,6-bisphosphate. Eur J Biochem 129: 191-195, 1982. 
81. Vanoverschelde JL, Janier MF, Bakke JE, Marshall DR, and Bergmann SR. Rate of 
glycolysis during ischemia determines extent of ischemic injury and functional recovery 
after reperfusion. Am J Physiol267: H1785-1794, 1994. 
105 
82. Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, and Epstein PN. 
Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. Am J Physiol 
Heart Circ Physiol294: H2889-2897, 2008. 
83. Weiss J and Hiltbrand B. Functional compartmentation of glycolytic versus oxidative 
metabolism in isolated rabbit heart. J Clin Invest 75: 436-447, 1985. 
84. Weiss IN and Lamp ST. Glycolysis preferentially inhibits ATP-sensitive K + channels 
in isolated guinea pig cardiac myocytes. Science 238: 67-69, 1987. 
85. Wu C, Okar DA, Newgard CB, and Lange AJ. Overexpression of6-phosphofructo-2-
kinase/fructose-2, 6-bisphosphatase in mouse liver lowers blood glucose by suppressing 
hepatic glucose production. J Clin Invest 107: 91-98, 2001. 
86. Wu C, Okar DA, Stoeckman AK, Peng LJ, Herrera AH, Herrera JE, Towle HC, and 
Lange AJ. A potential role for fructose-2,6-bisphosphate in the stimulation of hepatic 
glucokinase gene expression. Endocrinology 145: 650-658,2004. 
87. Xu J, Han J, Epstein PN, and Liu YQ. Regulation ofPDK mRNA by high fatty acid 
and glucose in pancreatic islets. Biochem Biophys Res Commun 344: 827-833,2006. 
88. Xu KY, Zweier JL, and Becker LC. Functional coupling between glycolysis and 
sarcoplasmic reticulum Ca2+ transport. Circ Res 77: 88-97, 1995. 
89. Ye G, Donthi RV, Metreveli NS, and Epstein PN. Overexpression of hexokinase 
protects hypoxic and diabetic cardiomyocytes by increasing A TP generation. Cardiovasc 
Toxicol5: 293-300, 2005. 
90. Ye G, Metreveli NS, Ren J, and Epstein PN. Metallothionein prevents diabetes-
induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. 
Diabetes 52: 777-783,2003. 
91. Zell R, Geck P, Werdan K, and Boekstegers P. TNF-alpha and IL-l alpha inhibit both 
pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence 
for primary impairment of mitochondrial function. Mol Cell Biochem 177: 61-67, 1997. 
92. Zhou YP, Ostenson CG, Ling ZC, and Grill V. Deficiency of pyruvate dehydrogenase 











Ph.D. Physiology and Biophysics, University of 
Louisville, School of Medicine, Department of 
Physiology & Biophysics, Louisville, KY 
B.S., Clinical Medicine, Guangdong Medical College of 
China, Department of Medicine, Zhanjiang, Guangdong, 
China 
Instructor, Department ofPathogenobiology , 
Guangdong Medical College, Zhanjiang, Guangdong, 
China 
Graduate Research Assistant, University of Louisville, 
School of Medicine, Department of Physiology & 
Biophysics 
Supervisor: Dr. Paul N. Epstein 
Thesis Title: 
"Elevation of cardiac glycolysis reduces pyruvate 
dehydrogenase but increases glucose oxidation 
107 








Peer reviewed Publications: 
Student's Scholarship of Guangdong Medical College of 
China 
Excellent Tri-A Student Award (good in study, attitude 
and health) of Guangdong Medical College of China 
Student's Scholarship of Guangdong Medical College of 
China 
Excellent Tri-A Student Award (good in study, attitude 
and health) of Guangdong Medical College of China 
Student's Scholarship of Guangdong Medical College of 
China 
Excellent Tri-A Student Pacesetter Award (good in study, 
attitude and health) of Guangdong Medical College of 
China 
University Scholarship & Fellowship, University of 
Louisville 
1. Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, Epstein PN. 
Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to 
hypoxia. Am J Physiol Heart Circ Physiol. 2008 Jun;294 (6):H2889-97. Epub 
2008 May 2. 
108 
2. Wang J, Song Y, Wang Q, Kralik PM, Epstein PN. Causes and characteristics of 
diabetic cardiomyopathy. 
3. Wang JX, Wang QW, He ZW, Ye F. Genetic instability in cancer tissues analyzed 
by RAPD PCR. Shi Yan Sheng Wu Xue Bao. 2001 Jun;34(2):151-5. Chinese. 
Manuscripts in preparation: 
1. Qianwen Wang, Jianxun Wang, and Paul N. Epstein Cardiomyocyte overexpression 
of kinase-active PFK-2 increases glucose oxidation despite decreased abundance and 
activity of pyruvate dehydrogenase complex 
2. Jianxun Wang, Qianwen Wang, Lewis 1. Watson, Steven P. Jones and Paul N. 
Epstein Cardiac overexpression of mitochondrial 8-oxoguanine DNA glycosylase 1 
protects against cardiac fibrosis following transaortic constriction 
3. Jianxun Wang, Qianwen Wang, Lewis 1. Watson, Steven P. Jones and Paul N. 
Decreased glycolysis increases susceptibility to cardiac hypertrophy and heart failure 
4. Jianxun Wang, Qianwen Wang, Lewis 1. Watson, Steven P. Jones and Paul N. 
Increased glycolysis increases susceptibility to cardiac hypertrophy and heart failure 
109 
